Volume 87 Issue 46 | p. 17 | Concentrates
Issue Date: November 16, 2009

Lonza Signs PACTs For Biomanufacturing

Department: Business
Keywords: Lonza, Arzerra

The Swiss contract manufacturer Lonza will manufacture Arzerra, a monoclonal antibody developed by GlaxoSmithKline and Genmab for the treatment of chronic lymphocytic leukemia. Arzerra was recently approved by FDA. Separately, Lonza’s Hopkinton, Mass., facility will manufacture ProChon Biotech’s fibroblast growth factor, a component of the Woburn, Mass., firm’s BioCart cartilage regeneration system. BioCart is now in clinical trials across the U.S., ProChon says.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment